Loading...

Cara Therapeutics

DB:69C
Snowflake Description

Flawless balance sheet with high growth potential.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
69C
DB
$717M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Cara Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The last earnings update was 40 days ago. More info.


Add to Portfolio Compare Print
69C Share Price and Events
7 Day Returns
-4.8%
DB:69C
-2.4%
DE Biotechs
1.8%
DE Market
1 Year Returns
60.8%
DB:69C
-10.2%
DE Biotechs
-6%
DE Market
69C Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Cara Therapeutics (69C) -4.8% -6.6% 19.7% 60.8% 169.9% 64.3%
DE Biotechs -2.4% 3.2% -7.7% -10.2% 51.2% 10.1%
DE Market 1.8% 4.6% 7.4% -6% 10.1% 15.3%
1 Year Return vs Industry and Market
  • 69C outperformed the Biotechs industry which returned -10.2% over the past year.
  • 69C outperformed the Market in Germany which returned -6% over the past year.
Price Volatility
69C
Industry
5yr Volatility vs Market
Related Companies

Value

 Is Cara Therapeutics undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Cara Therapeutics to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Cara Therapeutics.

DB:69C Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 8 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 8%
Perpetual Growth Rate 10-Year DE Government Bond Rate 0.2%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for DB:69C
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year DE Govt Bond Rate 0.2%
Equity Risk Premium S&P Global 6%
Biotechs Unlevered Beta Simply Wall St/ S&P Global 1.45
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.448 (1 + (1- 21%) (0%))
1.3
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.3
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 0.23% + (1.3 * 5.96%)
7.98%

Discounted Cash Flow Calculation for DB:69C using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Cara Therapeutics is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

DB:69C DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (USD, Millions) Source Present Value
Discounted (@ 7.98%)
2019 -80.00 Analyst x1 -74.09
2020 -97.00 Analyst x1 -83.20
2021 -91.00 Analyst x1 -72.29
2022 10.00 Analyst x1 7.36
2023 98.00 Analyst x1 66.77
2024 161.70 Est @ 65% 102.04
2025 235.39 Est @ 45.57% 137.57
2026 310.64 Est @ 31.97% 168.13
2027 380.37 Est @ 22.45% 190.66
2028 440.39 Est @ 15.78% 204.45
Present value of next 10 years cash flows $647.40
DB:69C DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2028 × (1 + g) ÷ (Discount Rate – g)
= $440.39 × (1 + 0.23%) ÷ (7.98% – 0.23%)
$5,697.08
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= $5,697.08 ÷ (1 + 7.98%)10
$2,644.77
DB:69C Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= $647.40 + $2,644.77
$3,292.17
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $3,292.17 / 39.55
$83.25
DB:69C Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in DB:69C represents 0.87398x of NasdaqGM:CARA
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
0.87398x
Value per Share
(Listing Adjusted, EUR)
= Value per Share (USD) x Listing Adjustment Factor
= $ 83.25 x 0.87398
€72.76
Value per share (EUR) From above. €72.76
Current discount Discount to share price of €15.85
= -1 x (€15.85 - €72.76) / €72.76
78.2%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price Cara Therapeutics is available for.
Intrinsic value
>50%
Share price is €15.85 vs Future cash flow value of €72.76
Current Discount Checks
For Cara Therapeutics to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • Cara Therapeutics's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • Cara Therapeutics's share price is below the future cash flow value, and at a substantial discount (> 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Cara Therapeutics's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Cara Therapeutics's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:69C PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in USD $-2.06
NasdaqGM:CARA Share Price ** NasdaqGM (2019-04-18) in USD $18.14
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 22.44x
Germany Market PE Ratio Median Figure of 424 Publicly-Listed Companies 19.59x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Cara Therapeutics.

DB:69C PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGM:CARA Share Price ÷ EPS (both in USD)

= 18.14 ÷ -2.06

-8.8x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Cara Therapeutics is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Cara Therapeutics is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Cara Therapeutics's expected growth come at a high price?
Raw Data
DB:69C PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -8.8x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 8 Analysts
37.5%per year
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.3x
Germany Market PEG Ratio Median Figure of 270 Publicly-Listed Companies 1.56x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Cara Therapeutics, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Cara Therapeutics's assets?
Raw Data
DB:69C PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in USD $3.38
NasdaqGM:CARA Share Price * NasdaqGM (2019-04-18) in USD $18.14
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.71x
Germany Market PB Ratio Median Figure of 574 Publicly-Listed Companies 1.84x
DB:69C PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGM:CARA Share Price ÷ Book Value per Share (both in USD)

= 18.14 ÷ 3.38

5.37x

* Primary Listing of Cara Therapeutics.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Cara Therapeutics is overvalued based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Cara Therapeutics's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Cara Therapeutics has a total score of 2/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Cara Therapeutics expected to perform in the next 1 to 3 years based on estimates from 8 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
37.5%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Cara Therapeutics expected to grow at an attractive rate?
  • Cara Therapeutics's earnings growth is expected to exceed the low risk savings rate of 0.2%.
Growth vs Market Checks
  • Cara Therapeutics's earnings growth is expected to exceed the Germany market average.
  • Cara Therapeutics's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:69C Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:69C Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 8 Analysts 37.5%
DB:69C Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 8 Analysts 51.8%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.5%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.6%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:69C Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 8 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:69C Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 315 184 87 5
2022-12-31 188 76 17 5
2021-12-31 74 -64 -88 3
2020-12-31 28 -74 -89 8
2019-12-31 20 -37 -92 7
DB:69C Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-12-31 13 -22 -74
2018-09-30 8 -9 -68
2018-06-30 3 1 -61
2018-03-31 0 -52 -53
2017-12-31 1 -55 -58
2017-09-30 1 -57 -66
2017-06-30 1 -60 -65
2017-03-31 1 -59 -69
2016-12-31 0 -47 -57
2016-09-30 0 -38 -45
2016-06-30 3 -33 -38
2016-03-31 3 -26 -31

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Cara Therapeutics's earnings are expected to grow significantly at over 20% yearly.
  • Cara Therapeutics's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:69C Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 8 Analyst Estimates (S&P Global) See Below

All data from Cara Therapeutics Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:69C Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 1.89 3.13 1.16 4.00
2022-12-31 0.41 1.69 -0.53 4.00
2021-12-31 -1.95 -1.19 -2.62 5.00
2020-12-31 -2.04 -1.11 -2.54 8.00
2019-12-31 -2.28 -1.89 -2.67 8.00
DB:69C Past Financials Data
Date (Data in USD Millions) EPS *
2018-12-31 -2.06
2018-09-30 -1.98
2018-06-30 -1.85
2018-03-31 -1.62
2017-12-31 -1.86
2017-09-30 -2.21
2017-06-30 -2.28
2017-03-31 -2.52
2016-12-31 -2.10
2016-09-30 -1.64
2016-06-30 -1.42
2016-03-31 -1.19

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Cara Therapeutics will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Cara Therapeutics's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Cara Therapeutics has a total score of 5/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Cara Therapeutics performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Cara Therapeutics's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Cara Therapeutics does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Cara Therapeutics's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Cara Therapeutics's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Cara Therapeutics's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Cara Therapeutics Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:69C Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 13.47 -74.01 15.32
2018-09-30 7.94 -67.54 13.60
2018-06-30 2.87 -60.58 14.18
2018-03-31 0.00 -52.69 13.17
2017-12-31 0.91 -58.13 11.87
2017-09-30 0.91 -65.92 10.92
2017-06-30 0.91 -65.02 9.21
2017-03-31 0.99 -68.79 9.19
2016-12-31 0.09 -57.28 9.23
2016-09-30 0.09 -44.84 9.36
2016-06-30 2.53 -38.08 9.12
2016-03-31 3.32 -30.69 8.40
2015-12-31 3.80 -24.69 7.77
2015-09-30 4.72 -19.33 7.40
2015-06-30 3.40 -21.09 7.06
2015-03-31 3.49 -19.05 6.61
2014-12-31 3.18 -17.75 6.18
2014-09-30 3.24 -15.67 5.49 0.70
2014-06-30 3.13 -13.70 4.77 1.53
2014-03-31 12.14 -5.93 4.33 2.86
2013-12-31 11.96 -3.07 3.52
2013-09-30 10.99 -2.78 3.16 2.75
2013-06-30 10.60 0.63 3.32 4.01
2013-03-31 0.91 -5.15 2.85 2.68
2012-12-31 1.19 -6.27 2.83 2.68

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Cara Therapeutics has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Cara Therapeutics has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Cara Therapeutics improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Cara Therapeutics's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Cara Therapeutics has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Cara Therapeutics's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Cara Therapeutics's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Cara Therapeutics is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Cara Therapeutics's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Cara Therapeutics's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Cara Therapeutics has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Cara Therapeutics Company Filings, last reported 3 months ago.

DB:69C Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 133.63 0.00 161.38
2018-09-30 149.53 0.00 206.08
2018-06-30 73.08 0.00 131.96
2018-03-31 72.10 0.00 74.52
2017-12-31 86.78 0.00 92.57
2017-09-30 99.07 0.00 102.98
2017-06-30 109.22 0.00 112.44
2017-03-31 29.27 0.00 36.81
2016-12-31 50.73 0.00 58.28
2016-09-30 71.80 0.00 71.42
2016-06-30 82.59 0.00 84.76
2016-03-31 94.93 0.00 96.24
2015-12-31 105.04 0.00 106.74
2015-09-30 113.86 0.00 111.12
2015-06-30 42.47 0.00 43.19
2015-03-31 47.42 0.00 47.42
2014-12-31 51.66 0.00 52.66
2014-09-30 55.34 0.00 58.39
2014-06-30 61.57 0.00 62.81
2014-03-31 64.73 0.00 67.04
2013-12-31 11.51 0.00 12.36
2013-09-30 13.59 0.31 17.73
2013-06-30 13.27 3.20 21.18
2013-03-31 0.39 0.78 1.12
2012-12-31 0.39 0.78 1.12
  • Cara Therapeutics has no debt.
  • Cara Therapeutics had no debt 5 years ago.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Cara Therapeutics has sufficient cash runway for more than 3 years based on current free cash flow.
  • Cara Therapeutics has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of -9.9% each year.
X
Financial health checks
We assess Cara Therapeutics's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Cara Therapeutics has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Cara Therapeutics's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Cara Therapeutics dividends. Estimated to be 0% next year.
If you bought €2,000 of Cara Therapeutics shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Cara Therapeutics's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Cara Therapeutics's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:69C Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 8 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 327 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:69C Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31
2020-12-31 0.00 1.00
2019-12-31 0.00 1.00

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Cara Therapeutics has not reported any payouts.
  • Unable to verify if Cara Therapeutics's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Cara Therapeutics's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Cara Therapeutics has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of Cara Therapeutics's dividends in 3 years as they are not expected to pay a notable one for Germany.
X
Income/ dividend checks
We assess Cara Therapeutics's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Cara Therapeutics afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Cara Therapeutics has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Cara Therapeutics's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Derek Chalmers
COMPENSATION $2,789,046
AGE 54
TENURE AS CEO 14.6 years
CEO Bio

Dr. Derek T. Chalmers, Ph.D., D.Sc. co-founded Cara Therapeutics, Inc. in 2004 and has been its Chief Executive Officer and President since September 2004. Dr. Chalmers served as a Principal Investigator at Neurocrine Biosciences (Nasdaq; NBIX). He co-founded Arena Pharmaceuticals (Nasdaq: ARNA) in 1997. He served as Vice President of Research of Arena Pharmaceuticals Inc., from April 1997 to May 1, 2004. From 1994 to January 1997, he directed various research programs at Neurocrine. From 1990 to 1994, he was engaged in research at the University of Michigan. Dr. Chalmers has over 24 years of experience in the biotechnology industry with increasing levels of corporate and business responsibilities. He has extensive corporate financing experience, having led both private and IPO road-show teams. He is an inventor or co-inventor on 31 issued or pending US patents. He has been a Director at Cara Therapeutics, Inc. since July 2004. He served as an Executive Director of Arena Pharmaceuticals Inc., from April 2000 to May 2004 and its Vice President from June 1997 to May 2004. Dr. Chalmers holds a Ph.D. in Neuroscience and Neuropharmacology from the University of Glasgow, Scotland.

CEO Compensation
  • Derek's compensation has been consistent with company performance over the past year.
  • Derek's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Cara Therapeutics management team in years:

1.1
Average Tenure
52
Average Age
  • The average tenure for the Cara Therapeutics management team is less than 2 years, this suggests a new team.
Management Team

Derek Chalmers

TITLE
Co-Founder
COMPENSATION
$3M
AGE
54
TENURE
14.6 yrs

Frédérique Menzaghi

TITLE
Chief Scientific Officer and Senior VP of R&D
COMPENSATION
$1M
AGE
52
TENURE
0.1 yrs

Joana Goncalves

TITLE
Chief Medical Officer
COMPENSATION
$4M
AGE
44
TENURE
0.5 yrs

Joe Stauffer

TITLE
Consultant
COMPENSATION
$2M
AGE
52
TENURE
0.5 yrs

Michael Lewis

TITLE
Co-Founder & Chief Scientific Advisor
AGE
66

Mani Mohindru

TITLE
CFO & Chief Strategy Officer
COMPENSATION
$4M
AGE
46
TENURE
1.7 yrs

Scott Terrillion

TITLE
Chief Compliance Officer
AGE
55
TENURE
2.4 yrs
Board of Directors Tenure

Average tenure and age of the Cara Therapeutics board of directors in years:

4.8
Average Tenure
55
Average Age
  • The tenure for the Cara Therapeutics board of directors is about average.
Board of Directors

Martin Vogelbaum

TITLE
Lead Independent Director
COMPENSATION
$332K
AGE
55

Derek Chalmers

TITLE
Co-Founder
COMPENSATION
$3M
AGE
54
TENURE
14.8 yrs

Harrison Bains

TITLE
Director
COMPENSATION
$284K
AGE
74
TENURE
4.8 yrs

Stanley Watson

TITLE
Member of the Scientific Advisory Board

James Kauer

TITLE
Member of the Scientific Advisory Board

Graeme Milligan

TITLE
Member of the Scientific Advisory Board

Philip Portoghese

TITLE
Member of the Scientific Advisory Board

Jeff Ives

TITLE
Director
COMPENSATION
$281K
AGE
67
TENURE
4.8 yrs

Chris Posner

TITLE
Director
COMPENSATION
$494K
AGE
48
TENURE
0.7 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
X
Management checks
We assess Cara Therapeutics's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Cara Therapeutics has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Cara Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells. Its lead product candidate includes KORSUVA (CR845/ difelikefalin) injection, which is in Phase III clinical trial for the treatment of patients with chronic kidney disease (CKD) associated pruritus undergoing hemodialysis, as well as in Phase II/III clinical trial for the treatment of dialysis patients suffering from chronic kidney disease-associated pruritus. The company is also developing Oral KORSUVA (CR845/difelikefalin) that is in Phase II clinical trial for the treatment of pruritus in stage III-V CKD patients; and in Phase I clinical trial for treating pruritus chronic liver disease. In addition, it is developing CR845/difelikefalin Injection, which is in Phase III clinical trial for the treatment of acute post-operative pain; and Oral CR845/difelikefalin that has completed Phase IIb for treating chronic pain, as well as CR701, which is in preclinical trial for the treatment of chronic pain. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing CR845/difelikefalin for acute pain and uremic pruritus in Japan; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing CR845/difelikefalin in South Korea. Cara Therapeutics, Inc. was founded in 2004 and is headquartered in Stamford, Connecticut.

Details
Name: Cara Therapeutics, Inc.
69C
Exchange: DB
Founded: 2004
$637,905,591
39,547,558
Website: http://www.caratherapeutics.com
Address: Cara Therapeutics, Inc.
4 Stamford Plaza,
9th Floor,
Stamford,
Connecticut, 06902,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGM CARA Common Stock Nasdaq Global Market US USD 31. Jan 2014
DB 69C Common Stock Deutsche Boerse AG DE EUR 31. Jan 2014
LSE 0HTC Common Stock London Stock Exchange GB USD 31. Jan 2014
Number of employees
Current staff
Staff numbers
55
Cara Therapeutics employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/21 21:38
End of day share price update: 2019/04/18 00:00
Last estimates confirmation: 2019/04/17
Last earnings filing: 2019/03/12
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.